RT Journal Article
SR Electronic
T1 Use of BIOFIRE® Pneumonia Panel Plus on sputum from patients with Cystic fibrosis or PCD
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 694
DO 10.1183/13993003.congress-2020.694
VO 56
IS suppl 64
A1 Philip Koliopoulos
A1 Julius Jurak
A1 Sebastian Schlotter
A1 Oliver Nitsche
A1 Kristin Bohn
A1 Daniel Schreiner
A1 Stephan Gehring
A1 Krystyna Poplawska
YR 2020
UL http://erj.ersjournals.com/content/56/suppl_64/694.abstract
AB Background: PCD and Cystic fibrosis are associated with chronic pulmonary infections. Pseudomonas aeruginosa (PA) or S. aureus (SA) cause a decline of lung function and determine antibiotic therapy. Viral infections influence onset of CF exacerbation. The BIOFIRE® Pneumonia Panel Plus comprises semiquantitative detection of 15 bacteria, 7 antibiotic resistance markers and 9 viruses.Aims: Can Biofire® POCT contribute to the early detection of CF-pathogens? We hypothesized a sensitive detection of PA and SA species as well as viral coinfections.Methods: From July - December 2019 sputum samples from in- or outpatients with CF or PCD were collected. Basic demographic and clinical data were obtained. Each sputum sample underwent Biofire® Pneumonia Panel Plus and culture-based testing.Results: 17 out- and 10 inpatients’ sputum samples were tested. 78% (21/27) had already received antibiotic treatment. POCT Biofire® detected viral coinfection in 8 cases. 19 samples were culture positive for PA, of which only 14 were detected by POCT. 17 were culture-positive for SA, of which 16 were detected by POCT. In 7 cases antibiotic resistance markers (mecA/C, MREJ) were found. The mean duration obtaining culture results was 9 days.Method: The POCT Biofire® showed ambiguous results detecting CF-pathogens. Concordance rate for PA was substantial and for SA good, according to Cohen’s kappa. The sensitivity of 73.7 % for PA might be due to false-negative classification when pathogens’ copies are quantified < 10^4/ml. The extended period to obtain culture results poses a limitation in clinical routine. POCT tools can be valuable screening for MRSA or viral coinfections.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 694.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).